Ortho Evra Patch Effectiveness and Advantages

Send to Friend | Bookmark | Live Chat

The popular contraceptive patch used by millions of American women, Ortho Evra has been linked to serious life-threatening side effects including blood clots, stoke, heart attacks, pulmonary embolisms, transient ischemic attacks, and deep venous thrombosis.

If you or a loved one have used the Ortho Evra Patch and developed a serious side effect, you should contact us immediately. You may be entitled to compensation and we can help.

What is the Problem?

The Food and Drug Administration announced that the Ortho Evra contraceptive patch is putting women at higher risk of developing deadly blood clots. Some four million women use the Ortho Evra Patch. The FDA is warning Ortho Evra Patch users that they're being exposed to about 60 percent more of the hormone estrogen than they would be if they were on the pill. That extra estrogen increases the risk of developing blood clots and other serious side effects.

In a recent survey, the Associated Press found that 17 relatively healthy women died from blood clots believed to be related to the Ortho Evra patch. But even before the Ortho Evra patch was approved, the FDA noticed non-fatal blood clots from it were three times higher than that of the pill.

Do I have an Ortho Evra Lawsuit?

The Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus exclusively on the representation of plaintiffs in Ortho Evra lawsuits. We are handling individual litigation nationwide and currently accepting new Ortho Evra side effect cases in all 50 states.

Attention Attorneys: We do not publish prior verdict/settlements. If you are an attorney and would like to refer us a case or for us to send you a profile of prior award judgments or average referral fees, please visit the attorney referral section of our website.

= Required Field

Ortho Evra Lawsuit News (National)

MRI Dye Linked To Potentially Fatal Skin Disease - Health Talk Health Canada is advising consumers of a notice sent to Canadian hospitals advising relevant health care professionals of safety concerns related to contrast agents containing gadolinium. These contrast agents have been linked to a rare and ...